Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.

Cited by papers we hold 2

• A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target · 2020
  No notice
• Advances in studies of tyrosine kinase inhibitors and their acquired resistance · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.